MISSION Therapeutics

MISSION Therapeutics is a specialist pharmaceutical company whose aim is to translate new molecular understandings of human cell biology into drugs that will markedly improve the management of life-threatening diseases, particularly cancer.

Mission Therapeutics holds and will maintain world-leadership in DNA repair and associated molecular pathways. Mission Therapeutics will use its knowledge and proven expertise in targeting these pathways for small-molecule drug discovery to develop new therapeutic agents with wide market potential. These drugs will mainly target "Achilles heels" of diseased tissues by exploiting the concept of synthetic-lethality.

Mission Therapeutics was founded by Professor Steve Jackson, a world expert on the DNA damage response. Steve is Senior Group Leader and Head of Cancer Research UK Laboratories in the Gurdon Institute, Cambridge University and is the University's Frederick James Quick Professor of Biology. For information on his research, see http://www.gurdon.cam.ac.uk/~jacksonlab/

For further information about the company, please write to: enquiries@missiontherapeutics.com

News
Aug 25, 2011
Press Release

MISSION THERAPEUTICS, A NEW CAMBRIDGE-BASED SPIN-OUT COMPANY, SECURES £6M IN SERIES-A FUNDING LED BY SOFINNOVA PARTNERS


[More]



Twitter

MISSIONTherapeu We are pleased to announce Dr Fritz Frickel's appointment as a non-executive director to the board of MISSION Therapeutics

MISSIONTherapeu MISSION Therapeutics is pleased to announce the recruitment of Dr Mark Kemp as head of chemistry

MISSIONTherapeu MISSION Therapeutics will be attending AACR 2012. Please contact to arrange meetings.

website design: motivateddesign.co.uk